

Ad hoc release

Ad-hoc Release pursuant to Section 15 of the German Securities Trading Act (Wertpapierhandelsgesetz)

Biofrontera AG resolves on capital increase

Leverkusen, Germany, February 16, 2016 – The Management Board of Biofrontera AG (FSE: B8F) has resolved on 12 February 2016, with the approval of the Supervisory Board, to increase the registered share capital of the Company by up to EUR 2,357,384 from authorized capital by issuing up to 2,357,384 new no-par registered shares (“New Shares”). The shareholders’ subscription right is excluded. The New Shares were offered to selected institutional investors at an issue price of EUR 1.90 per New Share, for a total issue price of EUR 4,479,029.60. All shares were successfully placed today.

The net proceeds of approx. EUR 4.4 mio will be used to cover the operational expenses of the Company and the further development of marketing the Company’s main product Ameluz®. Currently, Ameluz® is approved for the treatment of actinic keratosis in the EU. With the proceeds from this issue, the Company intends to support the regulatory approval and commercialization in the US as well as the extension of the European approval of Ameluz® for treatment of basal cell carcinoma.

The Management Board

Biofrontera AG, Hemmelrather Weg 201, 51377 Leverkusen
ISIN: DE0006046113
WKN: 604611

contact: Biofrontera AG
Tel.: +49 (0214) 87 63 2 0, Fax.: +49 (0214) 87 63 290
e-mail: press@biofrontera.com